MedTrace Logo

The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents

NCT00811980 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2011-11-24

No results posted yet for this study

Summary

We will determine if linezolid inhibits cellular activation and production of pro-inflammatory cytokines, providing mechanistic rationale for its clinical efficacy and the justification for further investigations in S. Aureus sepsis.

Conditions

Interventions

DRUG

Linezolid or Vancomycin

Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.

Sponsors & Collaborators

Principal Investigators

  • Guy Zimmerman, MD · University of Utah

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-06-30
Completion
2010-06-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00811980 on ClinicalTrials.gov